18F-Fluciclovine PET/CT to Identify Patients with Brain Metastasis

Inclusion Criteria

• Patients with clinically suspected or diagnosed brain metastatic lesion(s)
• Age ≥ 18 years
• Known history cancer
• Brain MRI in the past 2 months positive for metastatic disease
• Scheduled for treatment: Surgical resection, or stereotactic radiosurgery, or whole brain radiation therapy
• Can tolerate 18F-fluciclovine PET/CT exam (can lie still on their back for the duration of the scan)
• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

• Patients who do not meeting inclusion criteria.
• Patients who have had a brain biopsy of the index lesion(s) sooner than 4 weeks from the brain 18F-fluciclovine PET/CT (to minimize false positive uptake due to inflammation).
• Patients who have had prior brain surgery or radiation treatment of the index lesion(s).
• Patients who have had treatment of the index brain lesion(s) or initiation of systemic therapy after the last MRI and prior to the PET/CT scan.
• Prior history of localized brain treatment (surgery or stereotactic radiosurgery /fractionated stereotactic radiotherapy) allowed, if at least one index lesion is not adjacent to previous treatment (10% isodose line of prior radiation therapy [RT]). Patients with only index lesion(s) within 10% isodose line of prior treatment would be excluded. For example, if ALL index lesions are within the 2.2 gray (Gy) isodose line of previously treated lesions to 22 Gy in 1 fractions, the patient would be ineligible, however if there is 1 index lesion not in the prior radiation field, then that patient would be eligible but all other lesions in prior radiation fields would be excluded from analysis.
• Inability to tolerate 18F-fluciclovine PET/CT exam
• Enrollment delays patient care
• Concurrent or prior enrollment on other clinical trials would not exclude patients, as long as all other eligibility criteria are met.